Indirubin-derived 6BIGOE potently inhibits pro-inflammatory interleukin(IL)-1β and prostaglandin (PG)E2 release in human monocytes with unknown mode of action, which shall be revealed. Because of inappropriate physicochemical properties, 6BIGOE shall be encapsulated into nanoparticles based on polymers of lactic and glycolic acid, stabilized by stealth polymers and targeted with e.g. Arg-Gly-Asp (RGD) ligands. Bioactivities will be tested in primary human monocytes/macrophages and their co-cultures with endothelial cells as well as in the HET-CAV (hen’s egg test – chick area vasculosa).
